1. Scrip
  2. >>Business
  3. >>Earnings

Regeneron Hopes Its High-Dose Aflibercept Will Ease Eylea Pressure

Execs Expect BCMA Bispecific To Stand Out In Competitive Space

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Eylea sales were below consensus for the second quarter in a row, but aflibercept 8mg approval in late June could offset the decline. Also, a late 2023 filing is planned for linvoseltamab in myeloma.

Regeneron announced its first quarter 2023 earnings on 4 May • Source: Shutterstock

The anticipated approval of Regeneron Pharmaceuticals, Inc.’s high-dose formulation of aflibercept may help offset some of the pressure on Eylea (aflibercept) as the drug maker’s first quarter 2023 earnings show the drug’s sales coming in below expectations for the second quarter in a row. Meanwhile, executives expressed excitement about an upcoming presentation of data for the company’s bispecific antibody for multiple myeloma, another addition to its portfolio in a competitive space.

Regeneron announced its Q1 earnings on 4 May, reporting total revenues of $3.2bn, up 7% from $3bn in the first...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.